

POSTER PRESENTATION

Open Access

Design of clinical cardioprotection trials using CMR: impact of myocardial salvage index and a narrow inclusion window on sample size

Henrik Engblom^{1*}, Einar Heiberg¹, Svend Eggert Jensen², Jan Erik Nordrehaug³, Jean-Luc Dubois-Randé⁴, Sigrun Halvorsen⁵, Sasha Koul⁶, David Erlinge⁶, Dan Atar⁵, Marcus Carlsson¹, Håkan Arheden¹

From 18th Annual SCMR Scientific Sessions Nice, France. 4-7 February 2015

Background

Cardiac magnetic resonance imaging (CMR) can be used to determine both myocardial infarct (MI) size and myocardium at risk (MaR), enabling assessment of myocardial salvage index (MSI). MI size as assessed by hyperenhancement on late gadolinium enhancement (LGE) has been shown to decrease approximately 25% during the first week after infarction. The aim of this study was to determine to what extent assessment of MSI and a narrow inclusion window affect the number of patients needed to reach sufficient statistical power in a clinical CMR cardioprotection trial.


Methods

Control subjects (n=91) from the recent CHILL-MI¹ and MITOCARE² cardioprotection trials, examined by CMR 2-6 days after acute reperfusion therapy, were used to assess the difference in sample size required to reach sufficient statistical power when using MI size alone compared

to MSI as outcome variable. In addition, 22 patients undergoing CMR at day 1 and 7 after acute reperfused infarction from a previous follow-up study³ were included to assess to what extent sample size is affected by the decrease in hyperenhancement seen during the first week after infarction. The variability of MI size by LGE, MaR by contrast-enhanced SSFP and MSI was used to simulate 100.000 clinical trials for different assumed treatment effects to determine the number of patients needed to reach sufficient statistical power.

Results


For an assumed effect of 25 % reduction in MI size by a cardioprotection treatment, the number of patients needed to reach sufficient statistical power can be reduced by 48% (34 patients in each arm versus 65) if using MSI instead of MI size alone as outcome variable (Figure 1). If a fixed time point for the CMR examination



¹Cardiac MR group Lund, Dept. of Clinical Physiology, Lund University, Lund, Sweden

Full list of author information is available at the end of the article








Figure 2 Change in hyperenhancement (arrows) day 1 and 7 after acute reperfusion therapy in a patient with inferior infarction.

is used instead of an inclusion window of 1-7 days after infarction, the number of patients needed to reach sufficient statistical power decreased by 31% for infarct size alone and 23% for MSI. Figure 2 shows an example of the reduction of hyperenhancement between day 1 and 7.

Conclusions

There is a significant reduction in sample size needed to reach sufficient statistical power in CMR cardioprotection trials when using MSI instead of MI size alone as outcome variable. In addition, sample size can be further reduced by narrowing the inclusion window during the first week after the acute event.

Authors' details

¹Cardiac MR group Lund, Dept. of Clinical Physiology, Lund University, Lund, Sweden. ²Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark. ³Department of Cardiology, Haukeland University Hospital, Bergen, Norway. ⁴Department of Cardiology, Henri Mondor Hospital, Creteil, France. ⁵Department of Cardiology B, Oslo University Hospital Ullevål, and Faculty of Medicine, University of Oslo, Oslo, Norway. ⁶Department of Cardiology, Lund University Hospital and Lund University, Lund, Sweden.

Published: 3 February 2015

References

- 1. Erlinge, et al: JACC 2014, 63:1857-65.
- 2. Atar, et al: EHJ 2014, Epub ahead.
- 3. Engblom, et al: Circ Cl 2009, 2:47-55.

doi:10.1186/1532-429X-17-S1-P90

Cite this article as: Engblom *et al.*: Design of clinical cardioprotection trials using CMR: impact of myocardial salvage index and a narrow inclusion window on sample size. *Journal of Cardiovascular Magnetic Resonance* 2015 17(Suppl 1):P90.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

